IRMD insider sales disclosed under Rule 10b5-1 trading plan
Rhea-AI Filing Summary
IRADIMED Corp (IRMD) CEO, President, Chairman and Director Roger E. Susi reported open-market sales of common stock on November 3, 2025.
The filing lists six tranches by an indirect holder, the Phillip Susi 2008 Dynasty Trust, including 1,618 shares at a weighted average price of $83.85, 1,335 shares at $83.22, 900 shares at $81.71, 601 shares at $81.28, 446 shares at $79.82, and 100 shares at $84.60. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
Following the reported transactions, the filing shows 2,322,500 shares held indirectly by the Phillip Susi 2008 Dynasty Trust, 162,950 shares held indirectly by the Roger E. Susi Revocable Trust, and 2,062,500 shares held indirectly by the Matthew Susi 2008 Dynasty Trust. The reporting person disclaims beneficial ownership of certain securities except to the extent of pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Routine Form 4 disclosing planned insider sales under Rule 10b5-1.
The report details multiple open-market sales on November 3, 2025 by an indirect holder associated with Roger E. Susi. Each tranche notes a weighted average price, with execution ranges disclosed in footnotes, aligning with standard Section 16 reporting practices.
The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025, which pre-establishes trading parameters. The filing lists indirect holdings across named trusts and includes a standard disclaimer of beneficial ownership except to the extent of pecuniary interest.
As a Form 4, this is informational; actual impact depends on holder decisions and market context. Subsequent filings may provide additional transaction details as trades occur under the plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 446 | $79.82 | $36K |
| Sale | Common Stock | 601 | $81.28 | $49K |
| Sale | Common Stock | 900 | $81.71 | $74K |
| Sale | Common Stock | 1,335 | $83.22 | $111K |
| Sale | Common Stock | 1,618 | $83.85 | $136K |
| Sale | Common Stock | 100 | $84.60 | $8K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. This transaction was executed in multiple trades at prices ranging from $79.50 to $80.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $80.61 to $81.48. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $81.50 to $81.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $82.58 to $83.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $83.52 to $84.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
